MA42597A - 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 - Google Patents
2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1Info
- Publication number
- MA42597A MA42597A MA042597A MA42597A MA42597A MA 42597 A MA42597 A MA 42597A MA 042597 A MA042597 A MA 042597A MA 42597 A MA42597 A MA 42597A MA 42597 A MA42597 A MA 42597A
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydropyridines
- fluoromethyl
- fluoro
- phenyl
- amino
- Prior art date
Links
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical class F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500465 | 2015-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42597A true MA42597A (fr) | 2018-06-20 |
Family
ID=56615973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042597A MA42597A (fr) | 2015-08-12 | 2016-08-10 | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10011596B2 (fr) |
| EP (1) | EP3334720A1 (fr) |
| JP (1) | JP2018531889A (fr) |
| KR (1) | KR20180033524A (fr) |
| CN (1) | CN107849011A (fr) |
| AR (1) | AR105668A1 (fr) |
| AU (1) | AU2016305275A1 (fr) |
| BR (1) | BR112017007472A2 (fr) |
| CA (1) | CA2993630A1 (fr) |
| CL (1) | CL2018000375A1 (fr) |
| CO (1) | CO2018000798A2 (fr) |
| CR (1) | CR20180077A (fr) |
| DO (1) | DOP2018000040A (fr) |
| EA (1) | EA201890256A1 (fr) |
| EC (1) | ECSP18010535A (fr) |
| HK (1) | HK1253372A1 (fr) |
| IL (1) | IL257007A (fr) |
| MA (1) | MA42597A (fr) |
| MX (1) | MX2018001699A (fr) |
| NI (1) | NI201800020A (fr) |
| PE (1) | PE20181015A1 (fr) |
| PH (1) | PH12018500268A1 (fr) |
| RU (1) | RU2018104868A (fr) |
| TN (1) | TN2018000035A1 (fr) |
| TW (1) | TW201718543A (fr) |
| WO (1) | WO2017025559A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| EP3532064B1 (fr) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| BR112018017058A2 (pt) * | 2016-12-21 | 2019-07-02 | H Lundbeck As | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetra-hidropiridin-2-il-fenil-5-(metóxi-d3)-pirazina-2-carboxamidas e derivados fluorados do mesmo como inibidores de bace1 |
| RS62551B1 (sr) | 2017-12-14 | 2021-12-31 | H Lundbeck As | Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| EP3728250A1 (fr) | 2017-12-20 | 2020-10-28 | H. Lundbeck A/S | PYRAZOLO[3,4-beta]PYRIDINES ET IMIDAZO[1,5-beta]PYRIDAZINES UTILISÉES EN TANT QU'INHIBITEURS DE PDE1 |
| KR20210112968A (ko) | 2020-03-07 | 2021-09-15 | 장성환 | 양면 인쇄가 가능한 라벨 제조방법 |
| KR20230012296A (ko) | 2021-07-15 | 2023-01-26 | 장성환 | 양면 인쇄가 가능한 라벨 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0210391A (pt) | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| JP4472349B2 (ja) | 2002-02-12 | 2010-06-02 | スミスクライン ビーチャム コーポレーション | ｐ３８阻害薬として有用なニコチンアミド誘導体 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| KR101730937B1 (ko) | 2010-06-09 | 2017-04-27 | 얀센 파마슈티카 엔.브이. | 베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체 |
| KR20140051822A (ko) | 2011-01-12 | 2014-05-02 | 노파르티스 아게 | 옥사진 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| DK2663561T3 (en) | 2011-01-13 | 2016-06-06 | Novartis Ag | New heterocyclic derivatives and their use in treating neurological disorders |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| AU2012266544A1 (en) | 2011-06-07 | 2013-11-21 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| JP2015514073A (ja) | 2012-03-20 | 2015-05-18 | エラン ファーマシューティカルズ， リミテッド・ライアビリティ・カンパニー | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用 |
| WO2014056816A1 (fr) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | Association d'un anticorps aβ et d'un inhibiteur de bace |
| WO2014065434A1 (fr) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
| JP6389830B2 (ja) | 2013-03-01 | 2018-09-12 | アムジエン・インコーポレーテツド | ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法 |
| JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
| GEAP201814248A (en) | 2014-02-19 | 2018-04-10 | H Lundbeck As | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| MA40941A (fr) * | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| CR20170187A (es) * | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) * | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
-
2016
- 2016-08-10 JP JP2018506847A patent/JP2018531889A/ja active Pending
- 2016-08-10 US US15/233,463 patent/US10011596B2/en not_active Expired - Fee Related
- 2016-08-10 CA CA2993630A patent/CA2993630A1/fr not_active Abandoned
- 2016-08-10 MX MX2018001699A patent/MX2018001699A/es unknown
- 2016-08-10 TN TNP/2018/000035A patent/TN2018000035A1/en unknown
- 2016-08-10 BR BR112017007472A patent/BR112017007472A2/pt not_active Application Discontinuation
- 2016-08-10 CN CN201680045234.5A patent/CN107849011A/zh active Pending
- 2016-08-10 WO PCT/EP2016/069029 patent/WO2017025559A1/fr not_active Ceased
- 2016-08-10 MA MA042597A patent/MA42597A/fr unknown
- 2016-08-10 TW TW105125417A patent/TW201718543A/zh unknown
- 2016-08-10 PE PE2018000231A patent/PE20181015A1/es not_active Application Discontinuation
- 2016-08-10 AR ARP160102458A patent/AR105668A1/es unknown
- 2016-08-10 RU RU2018104868A patent/RU2018104868A/ru not_active Application Discontinuation
- 2016-08-10 HK HK18112668.6A patent/HK1253372A1/zh unknown
- 2016-08-10 KR KR1020187004062A patent/KR20180033524A/ko not_active Withdrawn
- 2016-08-10 EA EA201890256A patent/EA201890256A1/ru unknown
- 2016-08-10 US US15/751,765 patent/US20180244645A1/en not_active Abandoned
- 2016-08-10 EP EP16748316.3A patent/EP3334720A1/fr not_active Withdrawn
- 2016-08-10 AU AU2016305275A patent/AU2016305275A1/en not_active Abandoned
- 2016-08-10 CR CR20180077A patent/CR20180077A/es unknown
-
2018
- 2018-01-18 IL IL257007A patent/IL257007A/en unknown
- 2018-01-26 CO CONC2018/0000798A patent/CO2018000798A2/es unknown
- 2018-02-05 PH PH12018500268A patent/PH12018500268A1/en unknown
- 2018-02-06 NI NI201800020A patent/NI201800020A/es unknown
- 2018-02-08 DO DO2018000040A patent/DOP2018000040A/es unknown
- 2018-02-09 EC ECIEPI201810535A patent/ECSP18010535A/es unknown
- 2018-02-09 CL CL2018000375A patent/CL2018000375A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018531889A (ja) | 2018-11-01 |
| CR20180077A (es) | 2018-04-09 |
| HK1253372A1 (zh) | 2019-06-14 |
| EA201890256A1 (ru) | 2018-06-29 |
| CL2018000375A1 (es) | 2018-07-06 |
| US10011596B2 (en) | 2018-07-03 |
| TW201718543A (zh) | 2017-06-01 |
| CN107849011A (zh) | 2018-03-27 |
| ECSP18010535A (es) | 2018-04-30 |
| NI201800020A (es) | 2018-06-29 |
| AU2016305275A1 (en) | 2018-02-08 |
| DOP2018000040A (es) | 2018-04-30 |
| AR105668A1 (es) | 2017-10-25 |
| US20170044151A1 (en) | 2017-02-16 |
| TN2018000035A1 (en) | 2019-07-08 |
| CO2018000798A2 (es) | 2018-05-10 |
| US20180244645A1 (en) | 2018-08-30 |
| CA2993630A1 (fr) | 2017-02-16 |
| IL257007A (en) | 2018-03-29 |
| PH12018500268A1 (en) | 2018-08-13 |
| KR20180033524A (ko) | 2018-04-03 |
| WO2017025559A1 (fr) | 2017-02-16 |
| EP3334720A1 (fr) | 2018-06-20 |
| MX2018001699A (es) | 2018-05-07 |
| PE20181015A1 (es) | 2018-06-26 |
| BR112017007472A2 (pt) | 2018-01-23 |
| RU2018104868A (ru) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| IL272407A (en) | Molecules for use in pest control, and intermediates, preparations, and related processes | |
| IL256898A (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MA45591A (fr) | Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| MA41251A (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| MA43761A (fr) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj | |
| MA40941A (fr) | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| EP3385302A4 (fr) | Composition polymère | |
| ZA201702797B (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| EP3334726A4 (fr) | Compositions de plinabuline | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| IL252195B (en) | Molecules with use in pest control, and intermediate products, preparations and processes related to them | |
| ZA201701131B (en) | Novel 2,5-substituted pyrimidines as pde4 inhibitors | |
| EP3273075A4 (fr) | Organe de fixation | |
| EP3223820A4 (fr) | Composés iminopyrimidinones condensés oxacycliques en c5-c6 utilisés comme inhibiteurs de bace, compositions et utilisation associées | |
| FR3025204B1 (fr) | Copolymeres a blocs utilisables comme fluidifiants | |
| GB201513614D0 (en) | Compositions, compounds and methods and uses relating thereto | |
| IL262850A (en) | Derived from prostaglandin, preparations containing it and uses | |
| EP3191447A4 (fr) | Composés de s-imino-s-oxo iminothiazine en tant qu'inhibiteurs de bace, compositions, et leur utilisation | |
| EP3274089A4 (fr) | Composition de catalyseur présulfuré | |
| EP3118227A4 (fr) | Composition de 1-octène | |
| MA42604A (fr) | 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1 |